Answers are grounded in this paper and cite their sources.
We report the case of long-term persisting rheumatoid arthritis (RA), treated with CD20-CD19 CAR-T when it became associated with diffuse large B cell lymphoma (DLBCL), resulting in a sustained drug-free remission of the preceding RA, as well as of the subsequent DLBCL that formed the indication of the CAR-T therapy using zamtocabtagene autoleucel, with a 1-year follow-up. According to our best knowledge, this is the first published clinical case report of long-term persisting RA treated with CAR-T cell therapy.
No takes yet. Share an insight, caveat, or question.
Balogh et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: